Asparaginase

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Retrieved on: 
Thursday, November 2, 2023
Acute lymphoblastic leukemia, CRAC, T16, Asparaginase, LA, Society, Severity, ASH, Pancreatitis, TPN, AAP, St. Jude Children's Research Hospital, Patient, ALL, Parenteral nutrition, ICU, Pharmaceutical industry

LA JOLLA, Calif., Nov. 2, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced that there will be a presentation of data from the initial cohort of the CRSPA study of Auxora™ (zegocractin) in asparaginase-induced pancreatic toxicity (AIPT) in a poster presentation at the 65th Annual American Society of Hematology (ASH) Meeting & Exposition being held December 9-12, 2023 in San Diego, CA.

Key Points: 
  • The presentation includes results from the first cohort consisting of nine patients from the CRSPA study.
  • ONCASPAR™ and RYLAYZE™), a nearly identical ALL treatment protocol as used in the CRSPA study.
  • Additionally, no CRSPA patients required total parenteral nutrition (TPN), compared to 68.8% in the historical matched control group.
  • Presentation Title: Zegocractin to Reduce the Severity of Asparaginase Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: Results of the Phase 1 Portion of the CRSPA Study

AKC Canine Health Foundation Marks Pet Cancer Awareness Month with Three New Canine Cancer Grants

Retrieved on: 
Monday, May 1, 2023
Bone, Mutation, Lomustine, Clinical trial, Cancer, Research, LAPP, Cell, Cocker Spaniel, Dog, Immune system, Prednisone, Gland, AKC, Health, CHF, Lymphoma, Vaccine, Procarbazine, Asparaginase

RALEIGH, N,C., May 1, 2023 /PRNewswire/ -- The AKC Canine Health Foundation (CHF), a non-profit organization dedicated to advancing the health of all dogs, marks Pet Cancer Awareness Month each May to highlight the impact of its funded canine cancer research.

Key Points: 
  • RALEIGH, N,C., May 1, 2023 /PRNewswire/ -- The AKC Canine Health Foundation (CHF), a non-profit organization dedicated to advancing the health of all dogs, marks Pet Cancer Awareness Month each May to highlight the impact of its funded canine cancer research.
  • Already in 2023, CHF has awarded three new grants to study canine lymphoma, anal sac carcinoma, and bone cancer.
  • Therefore, approximately one quarter of CHF's active research portfolio is usually dedicated to studies exploring more accurate diagnostic tests and new treatments for canine cancer.
  • To learn more about the Foundation's commitment to canine cancer research, including educational resources and ways to participate in canine cancer research, please visit akcchf.org/caninecancer .

CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

Retrieved on: 
Monday, March 20, 2023
LLP, Doctor of Pharmacy, ALL, Acute lymphoblastic leukemia, ALI, CRAC, Pancreas, AP, Toxicity, AAP, AKI, Lung, Development, Acute kidney injury, Cooley LLP, Patient, Acute pancreatitis, Systemic inflammatory response syndrome, Kidney, Acute respiratory distress syndrome, Oppenheimer, Asparaginase, Research, White lung, SIRS, Pharmaceutical industry, Security (finance)

LA JOLLA, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (CalciMedica) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced the closing of its previously announced merger with Graybug Vision, Inc. CalciMedica’s stock will commence trading on March 21, 2023 on the Nasdaq Global Market under the trading symbol “CALC”.

Key Points: 
  • Immediately prior to the closing of the merger, CalciMedica completed the previously announced private placement of $10.3 million.
  • “With the closing of this merger, CalciMedica enters into a pivotal new phase of its future development, and we are extremely thankful to have partnered with Graybug for this transformational deal,” said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica.
  • Immediately following the merger, CalciMedica had approximately 5.5 million shares of common stock outstanding.
  • In connection with the merger, the parties waived the condition that the shares of Graybug Vision, Inc. common stock to be issued to CalciMedica stockholders in the merger be approved for listing on Nasdaq as of the closing of the merger.

Graybug and CalciMedica Enter into Definitive Merger Agreement

Retrieved on: 
Monday, November 21, 2022
Cooley LLP, Pharming, Tissue, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Systemic inflammatory response syndrome, Optimism, Asparaginase, Security (finance), Acute pancreatitis, AAP, Communication, AKI, Oppenheimer, IR, Patient, Necrosis, LA, Harvard University, Treasury, CRAC, FDA, Person, COVID-19, Growth, ALL, Acute kidney injury, LLP, Acute lymphoblastic leukemia, Food, Telephone, Mortality, AP, Johns Hopkins School of Medicine, Safety, Manifest and latent functions and dysfunctions, AHRF, Pancreatitis, Biomedical Research, Sale, Name, SIRS, Pharmaceutical industry, Holding company, Shareholder, MD

REDWOOD CITY, Calif. and LA JOLLA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) and CalciMedica Inc. (CalciMedica) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on further developing CalciMedica’s lead product candidate Auxora™, a proprietary, intravenous-formulated, small molecule calcium-release activated calcium (CRAC) channel inhibitor, to treat life-threatening inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure (AHRF), for which there are no currently approved therapies. Auxora, which modulates the immune response and protects against tissue cell injury, has been studied in four completed efficacy clinical trials, demonstrating positive and consistent clinical results, as well as a favorable safety profile. Subject to each company’s stockholder approval, the combined company is expected to trade on the Nasdaq Global Market.

Key Points: 
  • After completing a comprehensive strategic review, we determined that the proposed merger with CalciMedica would provide the best return for Graybug stockholders moving forward, said Frederic Guerard, Pharm.D., Chief Executive Officer of Graybug.
  • Im extremely pleased to announce this proposed merger with Graybug, which comes at a pivotal time for our company, said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica.
  • The merger agreement provides that the board of directors of the combined company will be composed of seven members, five selected by CalciMedica and two selected by Graybug.
  • In connection with the merger, Graybug intends to file with the SEC preliminary and definitive proxy statements relating to the proposed merger and any other relevant documents.

Asparaginase Global Market Report 2022: Rising Incidences of Leukemia and Increasing Usage Application Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 19, 2022
Pharmaceutical, Health, Oncology, Biomedical engineering, Leukemia, Transport, Growth, Population, Ammonia, Escherichia coli, Degenerative disease, CAGR, Asparaginase, Research, Food industry, Acute leukemia, R, Geography, Industry, Incidence, Nanomedicine, Food, T-Cell Acute Lymphoblastic Leukemia, Lymphoma, Allergy, COVID-19, Lymphoproliferative disorders, Pet, Fine chemical, Pharmaceutical industry

The global asparaginase market is expected to grow from US$ 564.01 million in 2021 to US$ 1,575.62 million by 2028.

Key Points: 
  • The global asparaginase market is expected to grow from US$ 564.01 million in 2021 to US$ 1,575.62 million by 2028.
  • The rising incidence of leukemia and the significant growth in the pharmaceutical and food industry are the major factors boosting the market.
  • Thus, an increasing population is contributing to the expansion in the food and pharmaceutical industries, driving the global asparaginase market.
  • The increasing demand for E. coli asparaginase in the cancer treatment and food processing industry promotes the growth of the global asparaginase market.

NEXT Molecular Analytics Receives Accreditation from the New York State Department of Health for its L-Asparaginase Enzyme Activity Assay Platform

Retrieved on: 
Thursday, June 9, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Certificate, New York State Department of Health, NYSDOH, NEXT, Acute lymphoblastic leukemia, Physician, Patient, Hospital, Asparaginase, United Arab Emirates, Drug discovery, Drug development, ALL, View, Fine chemical, Pharmaceutical industry

NEXT Bio Research Services LLC ( www.nextmolecular.com ), dba NEXT Molecular Analytics is pleased to announce that the New York State Department of Health (NYSDOH) has accredited the Companys L-Asparaginase enzyme activity assay platform.

Key Points: 
  • NEXT Bio Research Services LLC ( www.nextmolecular.com ), dba NEXT Molecular Analytics is pleased to announce that the New York State Department of Health (NYSDOH) has accredited the Companys L-Asparaginase enzyme activity assay platform.
  • This means that NEXT is now able to receive clinical test samples from New York State institutions without waiver and also means that NEXT is now accredited in all 50 states to process asparaginase test samples.
  • L-asparaginase chemotherapy is integral in the treatment of pediatric patients with acute lymphoblastic leukemia (ALL).
  • Its incorporation as part of a multi-agent chemotherapy regimen has resulted in improved, event free survival in childhood ALL.

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022

Retrieved on: 
Tuesday, May 24, 2022
Internet, 150, Document, Availability, Company, Medicine, CAC All-Tradable, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Catalent, Food, GMP, Organic acid, Survival, Metabolism, Nasdaq, Director, Annual, European Medicines Agency, Patient, Acute lymphoblastic leukemia, Mass meeting, Combined, Annual general meeting, Shareholder, FDA, Asparaginase, CAC, ISIN, Asparagine, IST, Board, Technology, CAC Mid 60, Adoption, ALL, Le Grand, Pancreatic cancer, Cancer, Growth, Fine chemical, Security (finance), Pharmaceutical industry, Euronext

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022

Key Points: 
  • ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022
    Cambridge, MA (U.S.) and Lyon (France), May 24, 2022 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the availability of the documents for its Annual General Meeting to be held on Friday, June 24, 2022.
  • ERYTECHs shareholders are hereby informed of the Annual General Meeting which will be held on June 24, 2022 at 09:00am CEST at the Htel Intercontinental Paris Le Grand, 2 rue Scribe, 75009 Paris (FRANCE).
  • Shareholders have access to the preparatory and information documents for the Shareholders Meeting as provided for by law and the regulations.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, May 17, 2022
150, Company, Medicine, CAC All-Tradable, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Catalent, Food, GMP, Organic acid, Survival, Metabolism, European Medicines Agency, CAC Mid 60, Patient, Acute lymphoblastic leukemia, Nasdaq, FDA, Asparaginase, CAC, ISIN, Asparagine, IST, Conference, Technology, ALL, Pancreatic cancer, Cancer, Growth, Pharmaceutical industry, Euronext

The corporate presentation will be held in person on Wednesday, May 25 at 10:30am ET and will be available on-line on the conference website afterwards.

Key Points: 
  • The corporate presentation will be held in person on Wednesday, May 25 at 10:30am ET and will be available on-line on the conference website afterwards.
  • For more information on the H.C. Wainwright 23rd Global Investment Conference, please visit the H.C. Wainwright Conference website https://hcwevents.com/globalconference/ .
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH Provides Business and Financial Update for the First Quarter of 2022

Retrieved on: 
Thursday, May 12, 2022
CEST, Income, 150, Company, R, Medicine, CAC All-Tradable, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Catalent, Food, GMP, Organic acid, Survival, Metabolism, ISIN, CAC Mid 60, Euronext, European Medicines Agency, Webcast, Patient, Acute lymphoblastic leukemia, Nasdaq, FDA, CAC, Asparaginase, Asparagine, IST, Conference, Technology, Marginal cost, Q&A, CMO, ALL, Pancreatic cancer, Cancer, Growth, CEO, Property management, Video game, Pharmaceutical industry

As of March 31, 2022, ERYTECH had cash and cash equivalents totaling 25.1 million (approximately $27.9 million), compared with 33.7 million as of December 31, 2021.

Key Points: 
  • As of March 31, 2022, ERYTECH had cash and cash equivalents totaling 25.1 million (approximately $27.9 million), compared with 33.7 million as of December 31, 2021.
  • The company does not plan to draw any further OCABSA tranche until the expiration of the financing facility in June 2022.
  • ERYTECH management will hold a conference call and webcast on Friday, May 13, 2022, at 8:30am ET / 2:30 pm CEST on the business highlights and financial results for the quarter ended March 31, 2022.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar

Retrieved on: 
Thursday, April 28, 2022
CAC Mid 60, Medicine, U.S. Securities and Exchange Commission, Euronext Paris, GMP, CAC All-Tradable, AMF, IST, Patient, FDA, Investor, CAC, Pancreatic cancer, Metabolism, Catalent, Cancer, Technology, Organic acid, Growth, Asparaginase, Food, Company, European Medicines Agency, Annual report, Asparagine, Euronext, ISIN, SEC, ALL, 150, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Survival, Nasdaq, Acute lymphoblastic leukemia, Pharmaceutical industry, Renewable energy

These documents can be accessed on the Investors section of the Companys corporate website ( www.erytech.com ).

Key Points: 
  • These documents can be accessed on the Investors section of the Companys corporate website ( www.erytech.com ).
  • In addition, the Universal Registration Document is available on the website of the AMF ( www.amf-france.org ) and the Annual Report on Form 20-F is also available on the website of the SEC ( www.sec.gov ).
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.